Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.

Item

http://www.wikidata.org/entity/Q33424261

Q33424261

about

Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review Chemotherapy-induced peripheral neurotoxicity: a critical analysis Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years Multiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patients Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis.CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not?Platinum-induced neurotoxicity and preventive strategies: past, present, and future Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Informative gene network for chemotherapy-induced peripheral neuropathy Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy.Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study.Can GSTM1 and GSTT1 polymorphisms predict clinical outcomes of chemotherapy in gastric and colorectal cancers? A result based on the previous reports.Treatment of pancreatic cancer: what can we really predict today?Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis.A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer p ERCC1: impact in multimodality treatment of upper gastrointestinal cancer.Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.Pharmacogenomics in neurology: current state and future steps.Gastric cancer pharmacogenetics: progress or old tripe?X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis.Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: Association between neurotoxicity and the GSTP1 polymorphism.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).Association of DNA repair and xenobiotic pathway gene polymorphisms with genetic susceptibility to gastric cancer patients in West Bengal, India.GSTP1 polymorphism predicts treatment outcome and toxicities for breast cancer.Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression.GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer.Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.

P2860

Q26824719-BA1CB19C-0D84-428F-A1F1-4E15E863049A Q27010318-D5C3F036-0548-47B5-8D7F-09CBCB0323B7 Q33391561-9D083F4B-9BE6-42BC-9359-EE65D7FF6152 Q34008793-DDB37CBA-72C8-4129-AD9D-F1000284C7C2 Q34177673-F9FB65C0-B8F7-4853-940A-A5D843F165ED Q34733071-758E672F-29BA-4817-8D65-A550ED73209F Q34745772-6CDD727E-B3A8-4341-81A9-3AAAC061BBC1 Q35109800-D2FE4E3F-1051-41AA-964F-01DB346240DB Q35194655-62C76944-2180-4BE1-A1DC-B8468B56B2F4 Q35196724-F06EFD3B-D6FB-45F6-BB77-C858A0F9C1F1 Q35345734-7E9FDA8E-5BCB-4D56-B79F-8C59C18FA3BE Q35584647-E9452519-653F-41D6-BCF7-4A04237FE19F Q35945680-95E1F154-E5B2-482C-9ACA-FAF0A11DE80A Q36111221-081F0AF8-E4EC-4DB8-8EF3-93B3996301EC Q36774217-6021ACC1-5908-456B-A845-5686204A131C Q36855556-ABB21F76-5755-4754-B6D3-076D746DB94D Q37042575-7583CC3A-58B2-43AA-9E75-B1C9D3EC50E3 Q37129815-EDC37147-1137-4B93-B90B-2CF00100DD62 Q37136248-F7484008-5A0A-425B-A002-B63A489E748B Q37499473-D72F3796-0575-4267-B3F5-5761F905FCF8 Q37580616-444285D0-1FC0-4047-8CC1-2892B51657B9 Q37818224-55BB5329-AFB7-43B3-8972-58716CD25C33 Q37887337-08165335-4148-43B1-92BF-D34631F2CBAF Q37967607-D49E7C61-6D38-4D9A-A5BF-081B86246283 Q38120288-102089DC-3A79-4950-B3BC-DD6EEEBE66A9 Q38162285-28735219-197A-451E-8150-73100C2391C4 Q38276429-0A2A75EE-F604-43A9-84DE-1554A2DAB9E3 Q38827826-F741C10A-B981-4D10-BBC9-9053CCD8508D Q38932560-84BA41B1-2AEF-47B7-8F4E-285569B4DE0E Q39566084-04A216F9-5ED6-49D6-A626-BE0016D97FBE Q39858558-32534B39-0A19-4B3C-8DFE-7C727D472E3E Q40107014-FB2FABDB-07D8-4886-A5BC-D4B95CE977C9 Q42700718-EAE2BE9C-B154-4A05-88F4-6EF774621610 Q42727098-BEE57DF7-73FA-44FC-BDDE-2C0A823F78CB Q43978326-F8FB6125-46FF-43CE-8161-1148E6257874 Q44734913-773394C3-D6F0-46F0-A27F-5A367AAC7233 Q47123679-C1BDCE50-702E-4E52-84D0-8654A97DADA6 Q47876292-B10B3941-F5F8-4515-B54D-1E9719005F01 Q51286494-4C26E184-D1FA-42B7-AB88-6294DE254E50 Q51436755-A5979CBC-EA09-4BC8-9AE7-136899244B04

P2860

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.

Item

http://www.wikidata.org/entity/Q33424261

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu